Clinical trial
Single-blind, Randomized, Placebo-controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JTT-662 Administered for 28 Days in Subjects With Type 2 Diabetes Mellitus on Metformin Monotherapy
NCT04465877 is registered in ClinicalTrials.gov with Akros Pharma Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Single-blind, Randomized, Placebo-controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JTT-662 Administered for 28 Days in Subjects With Type 2 Diabetes Mellitus on Metformin Monotherapy
- Lead sponsor
- Akros Pharma Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 15, 2020
- Completion date
- February 17, 2021
- Enrollment
- 37 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.